218 related articles for article (PubMed ID: 2828758)
1. Cytomegalovirus (CMV) infections in patients receiving CMV-IgG-hyperimmunoglobulin prophylaxis after bone-marrow transplantation.
Schmeiser T; Heit W; Arnold R; Bunjes D; Wiesneth M; Hertenstein B; Hampl W; Heimpel H
Klin Wochenschr; 1987 Oct; 65(20):967-74. PubMed ID: 2828758
[TBL] [Abstract][Full Text] [Related]
2. [Risk factors for the occurrence of pneumonia caused by cytomegaloviruses in patients with bone marrow transplants during prevention with cytomegalovirus hyperimmune globulin].
Schmeiser T; Heit W
Immun Infekt; 1985 Nov; 13(6):302-6. PubMed ID: 3000924
[TBL] [Abstract][Full Text] [Related]
3. [Cytomegalovirus hyperimmune globulin prophylaxis in bone marrow transplants in children with various diseases].
Ebell W; Blütters-Sawatzki R; Friedrich W; Hampl W; Kleihauer E
Immun Infekt; 1985 Nov; 13(6):307-12. PubMed ID: 3000925
[TBL] [Abstract][Full Text] [Related]
4. Pre-transplant cytomegalovirus immunoglobulin G antibody levels could prevent severe cytomegalovirus infections post-transplant in liver transplant recipients: Experience from a tertiary care liver centre.
Gupta E; Pamecha V; Verma Y; Kumar N; Rastogi A; Hasnian N; Bhadoria AS
Indian J Med Microbiol; 2017; 35(4):499-503. PubMed ID: 29405140
[TBL] [Abstract][Full Text] [Related]
5. Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections.
Grob JP; Grundy JE; Prentice HG; Griffiths PD; Hoffbrand AV; Hughes MD; Tate T; Wimperis JZ; Brenner MK
Lancet; 1987 Apr; 1(8536):774-6. PubMed ID: 2882184
[TBL] [Abstract][Full Text] [Related]
6. The importance of pre bone marrow transplantation serology in determining subsequent cytomegalovirus infection. An analysis of risk factors.
Paulin T; Ringdén O; Lönnqvist B; Wahren B; Nilsson B
Scand J Infect Dis; 1986; 18(3):199-209. PubMed ID: 3016884
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus seroconversion in patients receiving intensive induction therapy prior to allogeneic bone marrow transplantation.
Kelsey SM; Newland AC
Bone Marrow Transplant; 1989 Sep; 4(5):543-6. PubMed ID: 2551435
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus prophylaxis and treatment following bone marrow transplantation.
Tsinontides AC; Bechtel TP
Ann Pharmacother; 1996 Nov; 30(11):1277-90. PubMed ID: 8913411
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis of CMV infection in bone marrow transplant recipients by hyperimmune CMV gamma-globulin.
Condie RM; O'Reilly RJ
Dev Biol Stand; 1982; 52():501-13. PubMed ID: 6299859
[TBL] [Abstract][Full Text] [Related]
10. Seronegative blood products prevent primary cytomegalovirus infection after bone marrow transplantation.
Mackinnon S; Burnett AK; Crawford RJ; Cameron S; Leask BG; Sommerville RG
J Clin Pathol; 1988 Sep; 41(9):948-50. PubMed ID: 2848062
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation.
Zekri AR; Mohamed WS; Samra MA; Sherif GM; El-Shehaby AM; El-Sayed MH
Transpl Immunol; 2004 Dec; 13(4):305-11. PubMed ID: 15589744
[TBL] [Abstract][Full Text] [Related]
12. CMV infections in bone marrow transplanted patients--evaluation of prophylaxis with Cytotect (CMV hyperimmuneglobulin).
Zintl F; Färber I; Hermann J; Fuchs D; Prager J; Wutzler P
Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(3-4):557-64. PubMed ID: 2480308
[TBL] [Abstract][Full Text] [Related]
13. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group.
Ruutu T; Ljungman P; Brinch L; Lenhoff S; Lönnqvist B; Ringdén O; Ruutu P; Volin L; Albrechtsen D; Sallerfors B; Ebeling F; Myllylä G
Bone Marrow Transplant; 1997 Feb; 19(3):233-6. PubMed ID: 9028551
[TBL] [Abstract][Full Text] [Related]
14. Salivary immunoglobulins in recipients of bone marrow grafts. III. A longitudinal follow-up of CMV specific antibodies.
Chaushu G; Chaushu S; Slavin S; Or R; Garfunkel AA; Yefenof E
Bone Marrow Transplant; 1996 Feb; 17(2):237-41. PubMed ID: 8640173
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for cytomegalovirus infection in BMT recipients transfused exclusively with seronegative blood products.
Rubie H; Attal M; Campardou AM; Gayet-Mengelle C; Payen C; Sanguignol F; Calot JP; Charlet JP; Robert A; Huguet F
Bone Marrow Transplant; 1993 Mar; 11(3):209-14. PubMed ID: 8385522
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of cytomegalovirus IgG antibody following infusion of a hyperimmune globulin preparation in allogeneic marrow transplant recipients.
Reusser P; Osterwalder B; Gratama JW; The TH; Gratwohl A; Speck B
Bone Marrow Transplant; 1989 May; 4(3):267-72. PubMed ID: 2543469
[TBL] [Abstract][Full Text] [Related]
17. [Modification of the incidence and course of CMV infections following kidney transplantation by passive immunization--initial experiences with a hyperimmunoglobulin].
Hoyer J; Dennin RH; Schulz E
Immun Infekt; 1985 Nov; 13(6):285-9. PubMed ID: 3000921
[TBL] [Abstract][Full Text] [Related]
18. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis.
Li CR; Greenberg PD; Gilbert MJ; Goodrich JM; Riddell SR
Blood; 1994 Apr; 83(7):1971-9. PubMed ID: 8142663
[TBL] [Abstract][Full Text] [Related]
19. [Importance of screening for antibodies to cytomegalovirus in organ transplantation].
Milbradt H; Flik J; Stangel W; Heigel R
Beitr Infusionsther; 1990; 26():33-6. PubMed ID: 1703866
[TBL] [Abstract][Full Text] [Related]
20. [Experiences with transfusion of CMV tested blood preparations after bone marrow transplantation].
Luboldt W; Henneberg-Quester KB; Schaefer UW; Beelen DW; Quabeck K; Thraenhart O
Beitr Infusionsther; 1990; 26():190-3. PubMed ID: 1703827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
